1003859-11-7

Basic information

• Product Name: 3-Bromo-5-bromomethyl-2-chloro-pyridine
• Synonyms: 3-Bromo-5-bromomethyl-2-chloro-pyridine
• CAS NO: 1003859-11-7
• Molecular Formula: C₆H₄Br₂ClN
• Molecular Weight: 285.36366
• Mol File: 1003859-11-7.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 317.8±37.0 °C(Predicted)
• Appearance: /
• Density: 2.034±0.06 g/cm3(Predicted)
• PKA: -1.66±0.10(Predicted)
• CAS DataBase Reference: 3-Bromo-5-bromomethyl-2-chloro-pyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Bromo-5-bromomethyl-2-chloro-pyridine(1003859-11-7)
• EPA Substance Registry System: 3-Bromo-5-bromomethyl-2-chloro-pyridine(1003859-11-7)

Safety Data

• Hazardous Substances Data: 1003859-11-7(Hazardous Substances Data)

Upstream product

• 17282-03-0 3-bromo-2-chloro-5-methyl-pyridine 
• 78686-77-8 5-bromo-6-chloro-3-pyridinecarboxylic acid methyl ester 
• 904745-59-1 (5-bromo-6-chloropyridin-3-yl)methanol 

Downstream Products

• 1311148-82-9 5-imidazol-1-ylmethyl-2,3-diphenyl-pyridine 

Relevant articles and documents

Scalable synthesis of a tetrasubstituted 7-azabenzofuran as a key intermediate for a class of potent HCV NS5B inhibitors

A series of tetrasubstituted 7-azabenzofurans displays remarkable pan-genotype inhibition of HCV NS5B polymerase. One of them has been identified as a potential clinical candidate. Completely different from the original synthesis of a common and key intermediate for this class of compounds, two novel and improved synthetic approaches are developed. Almost every step of the synthesis has been optimized, including several important but not fully explored transformations, such as radical bromination with methyl pyridine and cyanide substitution with TMSCN. The 7-azabenzofuran core is prepared by an acylation-heterocyclization reaction, using acyl chloride as both the reactant and the activation reagent for the N-oxide substrate. Compared with the BMS synthesis, the overall yield has been tripled, and those harmful or cost-effective synthetic steps have been reduced. Furthermore, a transition-metal-free synthetic method for the construction of 3-cyano substituted 7-azabenzofurans is presented.

Bromine structural domain inhibitor compound and application thereof

The invention relates to a bromine structural domain inhibitor and provides a compound shown in a general formula I, pharmaceutical salt, an enantiomer, a diastereoisomer, an atropisomer, racemate, apolymorphic substance and solvate of the compound or an isotope labelled compound (including a deuterium substituted compound), a preparation method of the compound, pharmaceutical composition containing the compound and an application of the above components in pharmaceuticals.

SELECTIVE CYP11B1 INHIBITORS FOR THE TREATMENT OF CORTISOL DEPENDENT DISEASES

The present invention relates to compounds which selectively inhibit CYP11B1. Preferably, the compounds of the present invention do not substantially inhibit CYP11B2. Moreover, the compounds of the present invention do not substantially inhibit CYP17 and/or CYP19, either. Amongst other applications of the compounds of the present invention, they can be used for the treatment of Cushing's syndrome or metabolic disease.